| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
Vitamin D2 (Ergocalciferol; Calciferol; Ercalciol) is one type of vitamin D that differs from vitamin D3 (which does not have a double bond on the side chain) in that it has one on the side chain. VDR agonist is what it is. As a dietary supplement, vitamin D2 is a naturally occurring substance that can be found in food. Vitamin D deficiency is treated and prevented with this supplement. This covers vitamin D insufficiency brought on by impaired intestinal absorption or liver disease. Hypoparathyroidism-related low blood calcium levels can also be treated with it. It can be injected into a muscle or taken orally.
| Targets |
Human Endogenous Metabolite
|
|---|---|
| ln Vivo |
After receiving omeprazole alone or in combination with either restricted food intake or Ergocalciferol for five weeks, the chickens weighed 15–25% less (P < 0.01) at sacrifice compared to the chickens given a vehicle or fed less[2].
In comparison to either ergocalciferol alone or fasting alone, the combination of the two treatments causes more growth impairments and facial abnormalities[3]. |
| References |
| Molecular Formula |
C28H44O
|
|---|---|
| Molecular Weight |
396.65
|
| Exact Mass |
396.34
|
| Elemental Analysis |
C, 84.79; H, 11.18; O, 4.03
|
| CAS # |
50-14-6
|
| Related CAS # |
5,6-trans-Vitamin D2;51744-66-2;(R)-Vitamin D2;116559-84-3;Vitamin D2-d6;1311259-89-8
|
| Appearance |
Solid powder
|
| SMILES |
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
|
| InChi Key |
MECHNRXZTMCUDQ-RKHKHRCZSA-N
|
| InChi Code |
InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
|
| Chemical Name |
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
|
| Synonyms |
Viosterol; Vitamin D2; Ergocalciferol; Ercalciol; calciferol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (3). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~31.3 mg/mL (78.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (5.24 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5211 mL | 12.6056 mL | 25.2111 mL | |
| 5 mM | 0.5042 mL | 2.5211 mL | 5.0422 mL | |
| 10 mM | 0.2521 mL | 1.2606 mL | 2.5211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05549154 | Recruiting | Drug: low-dose vitamin D2 softgels Drug: placebo |
Vitamin D Deficiency Chronic Kidney Disease 5D |
Jina Pharmaceuticals Inc. | December 5, 2022 | Not Applicable |
| NCT03621553 | Active Recruiting |
Drug: Placebo Drug: Ergocalciferol |
Sarcoidosis Vitamin D Insufficiency |
University of Texas Southwestern Medical Center |
July 1, 2010 | Phase 4 |
| NCT04450199 | Recruiting | Drug: Vitamin D2 Other: Placebo |
Vitamin D Deficiency | Allegheny Singer Research Institute |
July 24, 2020 | Early Phase 1 |
| NCT05458024 | Recruiting | Drug: Vitamin D 2 Drug: Vitamin D2 Placebo |
Musculoskeletal Pain | University of North Carolina, Chapel Hill |
December 8, 2022 | Phase 2 |
| NCT05673980 | Recruiting | Drug: Vitamin D 2 Other: placebo |
Healthy Volunteers | Peking University Third Hospital | December 18, 2022 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
